These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 9572647)

  • 1. Difference in pharmacological activity between CPH 82 and podophyllotoxin.
    Rosén B
    Scand J Rheumatol; 1998; 27(2):159. PubMed ID: 9572647
    [No Abstract]   [Full Text] [Related]  

  • 2. Endocrine effects of the podophyllotoxine derivative drug CPH 82 (Reumacon) in patients with rheumatoid arthritis.
    Carlström K; Hedin PJ; Jönsson L; Lerndal T; Lien J; Weitoft T; Axelson M
    Scand J Rheumatol; 2000; 29(2):89-94. PubMed ID: 10777121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CPH 82 (Reumacon) in refractory inflammatory arthritis.
    Gudmundsdóttir ES; Jónsson H
    Scand J Rheumatol; 2000; 29(5):323-5. PubMed ID: 11093600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucocorticoid-like anti-inflammatory versus immunosuppressive effects of CPH 82 as a single drug therapy of moderately active rheumatoid arthritis patients.
    Masi AT; Chatterton RT
    Scand J Rheumatol; 2000; 29(2):85-8. PubMed ID: 10777120
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of CPH82 in rheumatoid arthritis. Accumulation of bone marrow cells in mitosis and clinical response.
    Rantapää-Dahlqvist S; Löfvenbert E; Norberg B
    Clin Rheumatol; 1993 Dec; 12(4):541-2. PubMed ID: 8124923
    [No Abstract]   [Full Text] [Related]  

  • 6. CPH 82.
    BioDrugs; 2003; 17(5):373-4. PubMed ID: 14498767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A clinical study of CPH 82 vs methotrexate in early rheumatoid arthritis.
    Lerndal T; Svensson B
    Rheumatology (Oxford); 2000 Mar; 39(3):316-20. PubMed ID: 10788542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CPH-82 (Reumacon) versus auranofin (Ridaura): a 36-week study of their respective onset of action rates in RA.
    Bjørneboe O; Moen F; Nygaard H; Haavik TK; Svensson B
    Scand J Rheumatol; 1998; 27(1):26-31. PubMed ID: 9506874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromosomal changes in rheumatoid arthritis patients treated with CPH82.
    Rantapää Dahlqvist S; Nordenson I
    Clin Rheumatol; 1996 Nov; 15(6):584-9. PubMed ID: 8973868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Podophyllum derivatives (CPH 82) compared with placebo in the treatment of rheumatoid arthritis.
    Larsen A; Petersson I; Svensson B
    Br J Rheumatol; 1989 Apr; 28(2):124-7. PubMed ID: 2706415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interference with the cortisol axis by the microtubule antagonist, CPH82.
    Dahlqvist SR; Olsson T
    Br J Rheumatol; 1993 Sep; 32(9):804-6. PubMed ID: 8396491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213).
    Nissen NI; Larsen V; Pedersen H; Thomsen K
    Cancer Chemother Rep; 1972 Dec; 56(6):769-77. PubMed ID: 4634038
    [No Abstract]   [Full Text] [Related]  

  • 13. Deoxypodophyllotoxin, a naturally occurring lignan, inhibits the passive cutaneous anaphylaxis reaction.
    Lin CX; Son MJ; Ju HK; Moon TC; Lee E; Kim SH; Kim MJ; Son JK; Lee SH; Chang HW
    Planta Med; 2004 May; 70(5):474-6. PubMed ID: 15124098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell cycle effects of the anti-rheumatic agent CPH82.
    Rantapää Dahlqvist S; Landberg G; Roos G; Norberg B
    Br J Rheumatol; 1994 Apr; 33(4):327-31. PubMed ID: 7908845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of CPH 82 on the growth of human lymphocytes in vitro. Definition of cytobiological action.
    Rantapää Dahlqvist S; Norberg B; Sondell K; Nordenson I; Holmgren G
    Br J Rheumatol; 1989 Oct; 28(5):418-21. PubMed ID: 2790402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammatory parameters in rheumatoid arthritis during and after administration of an anti-mitotic agent (Podophyllum lignan derivatives).
    Berglund K; Johansson BG; Laurell AB; Sjöholm A; Sturfelt G
    Scand J Rheumatol; 1978; 7(1):61-3. PubMed ID: 675176
    [No Abstract]   [Full Text] [Related]  

  • 17. Lignans and aromatic glycosides from Piper wallichii and their antithrombotic activities.
    Shi YN; Shi YM; Yang L; Li XC; Zhao JH; Qu Y; Zhu HT; Wang D; Cheng RR; Yang CR; Xu M; Zhang YJ
    J Ethnopharmacol; 2015 Mar; 162():87-96. PubMed ID: 25555357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiproliferative effects on human peripheral blood mononuclear cells and inhibition of in vitro immunoglobulin synthesis by Podophyllotoxin (CPH86) and by semisynthetic lignan glycosides (CPH82).
    Truedsson L; Geborek P; Sturfelt G
    Clin Exp Rheumatol; 1993; 11(2):179-82. PubMed ID: 8508560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Podophyllotoxin and its derivatives: Potential anticancer agents of natural origin in cancer chemotherapy.
    Motyka S; Jafernik K; Ekiert H; Sharifi-Rad J; Calina D; Al-Omari B; Szopa A; Cho WC
    Biomed Pharmacother; 2023 Feb; 158():114145. PubMed ID: 36586242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukaemia during podophyllotoxin treatment in a patient with juvenile chronic arthritis.
    Kauppi M; Savolainen HA; Anttila VJ; Isomäki HA
    Scand J Rheumatol; 1996; 25(5):340. PubMed ID: 8921932
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.